Is It Time to Rethink Standard Anticoagulation? Apixaban vs VKA in HeartMate 3 LVADs
Tania Ahuja, Clinical Assistant Professor, Assistant Director of Clinical Pharmacy and Clinical Pharmacotherapy Specialist, shared a post on X:
”Is it time to re-think anticoagulation for HeartMate3 (HM3) LVADs?
2 RCTs and 3 observational studies including 209 patients: 119 in the apixaban group and 90 in the VKA group demonstrating apixaban just as good as VKA and with less.”
Read the full article here.
Title: Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Authors: Andrea Tripoli, Miguel A. Samaniego, Norma N. Gamarra-Valverde, Shivraj Paneer Selvam, Edgardo Kaplinsky, Alejandro Barbagelata, Anna Mara Scandroglio, Juliana Giorgi
Stay updated on all science in the field of hematology with Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque